Current Report Filing (8-k)
January 21 2020 - 4:48PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
_____________
FORM
8-K
_____________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): January 21, 2020
ONCOSEC
MEDICAL INCORPORATED
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
000-54318
|
|
98-0573252
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File Number)
|
|
Identification No.)
|
3565
General Atomics Court, Suite 100
San
Diego, California 92121
24
North Main Street
Pennington,
NJ 08534-2218
(Address
of Principal Executive Offices)
(855)
662-6732
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act.
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act.
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange Act.
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
|
ONCS
|
|
NASDAQ
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
|
On
January 21, 2020, OncoSec Medical Incorporated (the “Company”) announced that Ms. Sara Bonstein, Chief Financial Officer
and Chief Operating Officer of the Company, would be stepping down from her positions in the Company effective January 30, 2020.
Ms. Bonstein’s decision to resign from the Company was not the result of any disagreement with the Company on any matter
relating to the Company’s operations, policies or practices.
On January 21, 2020, the Company also announced that effective January 30, 2020, Mr. Robert J. DelAversano
would become the Company’s Principal Accounting Officer and Controller.
Robert
J. DelAversano, 48, is currently Executive Director of Finance of the Company. Mr. DelAversano has over fifteen years of experience
in accounting including thirteen years in public accounting. He will assume the role of Principal Accounting Officer and
Controller. Prior to joining the Company, Mr. DelAversano was the Director of Financial Reporting and Taxation at Brio Financial
Group (“Brio”), where he served as the firm’s Director of Financial Reporting and Taxation, consulting with
various public companies in financial reporting, internal control development and evaluation, budgeting and forecasting. Prior
to joining Brio, Mr. DelAversano was a manager at Bartolomei Pucciarelli, LLC. Within that capacity, Mr. DelAversano oversaw the
Accounting and Tax practice with industry focuses in real estate development and management, manufacturing and wholesalers, construction
contractors, and professional services firms and medical devices and services. In addition, he performed audit services, outsourced
chief financial officer functions, and/or consulted clients through difficult Securities and Exchange Commission comment periods
particularly through application of complex accounting principles for a vast public company client base.
No
family relationships exist between Mr. DelAversano and any of our directors or other executive officers. There are
no arrangements between Mr. DelAversano and any other person pursuant to which Mr. DelAversano was selected as our controller
and principal accounting officer, nor are there any transactions to which the Company is or was a participant and in which Mr. DelAversano
has a material interest subject to disclosure under Item 404(a) of Regulation S-K.
A
press release regarding the above is furnished hereto as Exhibit 99.1
Item 9.01
|
Financial Statements and Exhibits.
|
The
following exhibit is furnished as part of this report:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ONCOSEC MEDICAL INCORPORATED
|
|
(Registrant)
|
|
|
|
Date:
January 21, 2020
|
By:
|
/s/
Daniel J. O’Connor
|
|
Name:
|
Daniel
J. O’Connor
|
|
Title:
|
President
and Chief Executive Officer
|
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024